Carney Complex Calculator

About the Carney Complex Calculator

The Carney Complex Calculator evaluates diagnostic criteria for Carney Complex (CNC), a rare autosomal dominant multiple neoplasia syndrome. It helps clinicians and trainees organize the major and supplemental findings that support the diagnosis, rather than trying to keep every criterion in memory. That makes it easier to review a rare syndrome in a structured way before confirming whether the published criteria are met. It also helps keep a rare diagnostic checklist readable when multiple organ systems and findings are involved.

Carney Complex is characterized by spotty skin pigmentation (lentigines, blue nevi), cardiac and extracardiac myxomas, endocrine tumors (primary pigmented nodular adrenocortical disease/PPNAD, growth hormone-producing pituitary adenomas, thyroid tumors), psammomatous melanotic schwannomas, and other neoplasms. Diagnosis requires two or more major criteria, or one major criterion plus a confirmed PRKAR1A mutation or an affected first-degree relative.

Enter clinical findings to calculate the diagnostic score, review which criteria are met, and understand the significance of each finding. This calculator supports structured screening and documentation, but definitive diagnosis still requires genetic testing and specialist evaluation.

When This Page Helps

Use this calculator when you need a structured checklist against the published diagnostic criteria rather than reviewing each feature manually. It is useful for organizing clinical findings, documenting which major criteria are present, and deciding when genetics, cardiology, endocrinology, or specialist follow-up should be considered. It also helps keep a rare-disease workup readable when several findings have to be reviewed together in one note.

How to Use the Inputs

1. Check each clinical finding that is present in the patient.
2. The calculator automatically tallies major and supplemental criteria.
3. Review the diagnostic assessment based on criteria count.
4. Check for PRKAR1A mutation status if available.
5. Indicate family history of confirmed Carney Complex.
6. Review the summary and recommended next steps.

Example Calculation

Tips & Best Practices

• Skin lentigines in CNC typically cluster on the face (lips, eyelids, conjunctivae) and genitalia.
• Cardiac myxomas in young patients (<40) should always prompt evaluation for CNC.
• PPNAD may present with cyclical Cushing syndrome — symptoms wax and wane.
• Large-cell calcifying Sertoli cell tumors in boys are highly specific for CNC.
• Blue nevi in CNC are typically multiple and may include the rare epithelioid blue nevus.

Diagnostic Criteria for Carney Complex

The diagnosis of CNC requires clinical criteria supported by genetic and family data. Major criteria include: (1) spotty skin pigmentation with typical distribution (lips, conjunctivae, genital mucosa), (2) myxoma (cutaneous, cardiac, or breast), (3) primary pigmented nodular adrenocortical disease (PPNAD), (4) acromegaly due to GH-producing adenoma, (5) large-cell calcifying Sertoli cell tumor, (6) thyroid carcinoma or nodules in a young patient, (7) psammomatous melanotic schwannoma, (8) blue nevi (multiple or epithelioid), (9) breast ductal adenoma, (10) osteochondromyxoma.

Supplemental criteria include: affected first-degree relative, inactivating mutation of PRKAR1A gene, and paradoxical GH/cortisol responses to dexamethasone.

Genetic Testing

PRKAR1A sequencing is the primary genetic test. Over 125 different pathogenic variants have been identified, including nonsense mutations, frameshift mutations, and splice-site variants. Approximately 70% of individuals meeting clinical criteria will have a detectable PRKAR1A mutation. Negative genetic testing does not exclude the diagnosis, as other genetic loci may be involved.

Clinical Management

Management of CNC is multidisciplinary, involving endocrinology, cardiology, dermatology, and genetics. Cardiac myxomas pose the greatest acute risk due to embolization and obstruction. Annual echocardiography is the cornerstone of surveillance. Endocrine tumors are managed based on hormone excess — surgical excision for PPNAD, pituitary adenomas, and thyroid tumors as indicated.

Frequently Asked Questions

• How rare is Carney Complex?

  Carney Complex affects approximately 1 in 100,000 people. Over 750 cases have been reported in the literature. It follows autosomal dominant inheritance with variable expressivity, meaning affected family members may show different features.

• What gene causes Carney Complex?

  About 70% of cases are caused by inactivating mutations in PRKAR1A on chromosome 17q24.2, which encodes the regulatory subunit of protein kinase A. The remaining 30% may involve other loci, including a region on chromosome 2p16.

• What is PPNAD?

  Primary Pigmented Nodular Adrenocortical Disease is a form of ACTH-independent Cushing syndrome unique to Carney Complex. The adrenal glands contain small (<4mm) pigmented nodules. It can present at any age but is most common in the second and third decades.

• Are cardiac myxomas in Carney Complex different?

  Yes. Unlike sporadic cardiac myxomas (which are typically single, left atrial, in older women), CNC myxomas can be multiple, affect any cardiac chamber, occur at any age, and recur after excision. Regular echocardiographic surveillance is essential.

• What surveillance is recommended?

  Annual echocardiography, annual cortisol evaluation (dexamethasone suppression test), thyroid ultrasound every 3-5 years, annual testicular ultrasound in males, clinical examination for skin findings, and monitoring of IGF-1/GH levels. Follow-up is typically coordinated by endocrinology, cardiology, and genetics.

• Can Carney Complex be cured?

  There is no cure for the genetic condition, but individual tumors can be treated surgically. Bilateral adrenalectomy treats PPNAD. Cardiac myxomas are excised but may recur. Lifelong surveillance is required for early detection of new tumors.